TCM
RNAM

Tekla Capital Management’s Avidity Biosciences RNAM Stock Holding History

Tekla Capital Management’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-64,618
Closed -$1.05M – 175
2022
Q3 		$1.05M Sell
64,618
-20,600
-24% -$394K 0.04% 131
2022
Q2 		$1.24M Buy
85,218
+58,766
+222% +$874K 0.05% 127
2022
Q1 		$489K Buy
+26,452
New +$449K 0.02% 161

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Tekla Capital Management's RNAM Position: Q4 2022 in Review

Tekla Capital Management sold out of Avidity Biosciences (RNAM) in Q4 2022, closing a stake of 64,618 shares — an estimated $1.05M sold.

Tekla Capital Management first reported a position in RNAM in Q1 2022 and held it in 3 quarters. The position peaked at $1.24M in Q2 2022. 148 funds tracked by Wall St. Rank hold RNAM as of Q4 2022.

  • Tekla Capital Management reported no remaining Avidity Biosciences position as of Q4 2022 after selling out during the quarter.
  • Tekla Capital Management sold 64,618 Avidity Biosciences shares in Q4 2022, an estimated $1.05M.
  • Tekla Capital Management first reported a position in Avidity Biosciences in Q1 2022 and held it in 3 quarters.
  • Tekla Capital Management's Avidity Biosciences position peaked at $1.24M in Q2 2022.
  • 148 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2022.

Based on Tekla Capital Management's 13F filing for Q4 2022, filed 10 Feb 2023.